Literature DB >> 19532142

A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells.

Richard H Smith1, Justin R Levy, Robert M Kotin.   

Abstract

Scalable methods of recombinant adeno-associated virus (rAAV) production have gained much recent interest as the field of rAAV-mediated gene therapy approaches the clinic. In particular, the production of rAAV vectors in insect cells via the use of recombinant baculovirus technology has proven to be an efficient and scalable means of rAAV production. Here, we describe a method for the production of rAAV serotypes 1 and 2 in insect cells using a simplified baculovirus-AAV expression vector system coupled with particle purification via affinity chromatography. The number of separate baculovirus constructs required for rAAV production was reduced by genetically modifying the AAV rep gene to allow expression of the AAV-encoded replication enzymes, Rep78 and Rep52, from a single mRNA species and combining the modified rep gene with an AAV cap gene expression cassette in a single baculovirus construct. Additionally, we describe lysis, binding, and elution conditions compatible with a commercially available affinity medium (AVB Sepharose High Performance) used to purify rAAV particles to near homogeneity in a single chromatography step. Using the described method, we obtained an average yield of 7 x 10(4) purified rAAV particles per cell (range: 3.7 x 10(4) to 9.6 x 10(4)) from suspension cultures of recombinant baculovirus-infected insect cells.

Entities:  

Mesh:

Year:  2009        PMID: 19532142      PMCID: PMC2835045          DOI: 10.1038/mt.2009.128

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  26 in total

1.  A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5.

Authors:  Nicole Brument; Robert Morenweiser; Véronique Blouin; Estelle Toublanc; Isabelle Raimbaud; Yan Chérel; Sébastien Folliot; Florence Gaden; Pierre Boulanger; Gabrielle Kroner-Lux; Philippe Moullier; Fabienne Rolling; Anna Salvetti
Journal:  Mol Ther       Date:  2002-11       Impact factor: 11.454

2.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs.

Authors:  M Kozak
Journal:  Nucleic Acids Res       Date:  1984-01-25       Impact factor: 16.971

4.  Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV).

Authors:  C R O'Riordan; A L Lachapelle; K A Vincent; S C Wadsworth
Journal:  J Gene Med       Date:  2000 Nov-Dec       Impact factor: 4.565

5.  Insect cells as a factory to produce adeno-associated virus type 2 vectors.

Authors:  Masashi Urabe; Chuantian Ding; Robert M Kotin
Journal:  Hum Gene Ther       Date:  2002-11-01       Impact factor: 5.695

6.  Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo.

Authors:  G Gao; G Qu; M S Burnham; J Huang; N Chirmule; B Joshi; Q C Yu; J A Marsh; C M Conceicao; J M Wilson
Journal:  Hum Gene Ther       Date:  2000-10-10       Impact factor: 5.695

7.  Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography.

Authors:  Nikola Kaludov; Beverly Handelman; John A Chiorini
Journal:  Hum Gene Ther       Date:  2002-07-01       Impact factor: 5.695

Review 8.  Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology.

Authors:  Alejandro Negrete; Robert M Kotin
Journal:  Brief Funct Genomic Proteomic       Date:  2008-07-16

9.  Serum-free production and column purification of adeno-associated virus type 5.

Authors:  Richard H Smith; Chuantian Ding; Robert M Kotin
Journal:  J Virol Methods       Date:  2003-12       Impact factor: 2.014

10.  Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column.

Authors:  A Auricchio; M Hildinger; E O'Connor; G P Gao; J M Wilson
Journal:  Hum Gene Ther       Date:  2001-01-01       Impact factor: 5.695

View more
  103 in total

1.  Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping.

Authors:  Lawrence T Bish; Meg M Sleeper; Sean C Forbes; Bingjing Wang; Caryn Reynolds; Gretchen E Singletary; Dennis Trafny; Kevin J Morine; Julio Sanmiguel; Sylvain Cecchini; Tamas Virag; Adeline Vulin; Cyriaque Beley; Janet Bogan; James M Wilson; Krista Vandenborne; Joe N Kornegay; Glenn A Walter; Robert M Kotin; Luis Garcia; H Lee Sweeney
Journal:  Mol Ther       Date:  2011-12-06       Impact factor: 11.454

Review 2.  Progress and challenges in viral vector manufacturing.

Authors:  Johannes C M van der Loo; J Fraser Wright
Journal:  Hum Mol Genet       Date:  2015-10-30       Impact factor: 6.150

3.  Systemic Vascular Transduction by Capsid Mutant Adeno-Associated Virus After Intravenous Injection.

Authors:  Daniel M Lipinski; Chris A Reid; Sanford L Boye; James J Peterson; Xiaoping Qi; Shannon E Boye; Michael E Boulton; William W Hauswirth
Journal:  Hum Gene Ther       Date:  2015-09-29       Impact factor: 5.695

Review 4.  Genetic therapies for cystic fibrosis lung disease.

Authors:  Patrick L Sinn; Reshma M Anthony; Paul B McCray
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

5.  Peptide affinity reagents for AAV capsid recognition and purification.

Authors:  N Pulicherla; A Asokan
Journal:  Gene Ther       Date:  2011-04-14       Impact factor: 5.250

6.  Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.

Authors:  Brett D Dufour; Catherine A Smith; Randall L Clark; Timothy R Walker; Jodi L McBride
Journal:  Mol Ther       Date:  2014-01-06       Impact factor: 11.454

7.  Functional labeling of neurons and their projections using the synthetic activity-dependent promoter E-SARE.

Authors:  Takashi Kawashima; Kazuo Kitamura; Kanzo Suzuki; Mio Nonaka; Satoshi Kamijo; Sayaka Takemoto-Kimura; Masanobu Kano; Hiroyuki Okuno; Kenichi Ohki; Haruhiko Bito
Journal:  Nat Methods       Date:  2013-07-14       Impact factor: 28.547

8.  OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy.

Authors:  Mario Mietzsch; Sabrina Grasse; Catherine Zurawski; Stefan Weger; Antonette Bennett; Mavis Agbandje-McKenna; Nicholas Muzyczka; Sergei Zolotukhin; Regine Heilbronn
Journal:  Hum Gene Ther       Date:  2014-01-23       Impact factor: 5.695

Review 9.  Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy.

Authors:  Tamas Virag; Sylvain Cecchini; Robert M Kotin
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

10.  Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens.

Authors:  Elif Engin; Konstantin I Bakhurin; Kiersten S Smith; Rochelle M Hines; Lauren M Reynolds; Wannan Tang; Rolf Sprengel; Stephen J Moss; Uwe Rudolph
Journal:  Neuropsychopharmacology       Date:  2014-02-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.